Royal Society Open Science (Apr 2023)

Barbigerone prevents scopolamine-induced memory impairment in rats by inhibiting oxidative stress and acetylcholinesterase levels

  • Shareefa A. AlGhamdi,
  • Fahad A. Al-Abbasi,
  • Amira M. Alghamdi,
  • Asma B. Omer,
  • Obaid Afzal,
  • Abdulmalik S. A. Altamimi,
  • Abdulaziz Alamri,
  • Sami I. Alzarea,
  • Waleed Hassan Almalki,
  • Imran Kazmi

DOI
https://doi.org/10.1098/rsos.230013
Journal volume & issue
Vol. 10, no. 4

Abstract

Read online

The current study was designed for the evaluation of barbigerone on memory loss. In this experimental study, 24 Wistar rats (n = 6) were used. Control rats and scopolamine (SCOP)-treated control group rats were orally administered with 3 ml of 0.5% sodium carboxymethyl cellulose (vehicle), whereas barbigerone was (10 and 20 mg kg−1) administered orally to the rats from the test group. During the 14-day treatment, control group rats were given 3 ml kg−1 day−1 saline, and all other groups were administered SCOP (1 mg kg−1 day−1, i.p.) 1 h after barbigerone p.o. treatment. The spontaneous alternation activities, learning capacities of a rat's memory were tested with Morris water maze and Y-maze. Reduced glutathione, malondialdehyde, acetylcholine esterase (AChE) and catalase (CAT) levels were measured in rat brain tissue as oxidative stress/antioxidant markers. Moreover, the levels of tumour necrosis factor, interleukin-6 (IL-6) and IL-1β were also estimated. Treatment with barbigerone in SCOP-administered rats dramatically reduced SCOP-induced neurobehavioural deficits, oxidative stress and neuroinflammatory markers, improved endogenous antioxidants, and restored AChE activity. By improving cholinergic function and reducing oxidative damage, barbigerone could mitigate the effects of SCOP-induced changes in the brain.

Keywords